tranexamic acid has been researched along with Ovarian Neoplasms in 14 studies
Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to obtain an experimental tumor model as similar as possible to human ovarian cancer which often had a large amount of ascites and to assess the therapeutic value of tranexamic acid." | 7.67 | Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. ( Kato, K; Kikuchi, Y; Kita, T; Kizawa, I; Miyauchi, M; Oomori, K; Sugita, M; Tenjin, Y, 1987) |
| "In the present phase II trial, 26 heavily pretreated patients with advanced recurrent ovarian carcinoma were treated with tranexamic acid, 4-6 g per os daily for at least 3 months." | 7.66 | Tranexamic acid for the treatment of advanced ovarian carcinoma. ( Johnsson, JE; Sigurdsson, K; Tropé, C, 1983) |
| "High-dose tranexamic acid is more effective in reducing blood loss and blood transfusion without increasing the risk of postoperative complications." | 5.69 | Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial. ( Chai, M; He, Z; Wu, X; Xia, L; Yang, X; Zhang, J, 2023) |
| " A combination of aprotinin with tranexamic acid may be effective in preventing or delaying rebleeding after rupture of an intracerebral aneurysm; the addition of aprotinin seems to decrease the incidence of delayed cerebral vasospasm and ischaemic complications which are sometimes noted when tranexamic acid alone is used." | 4.77 | Clinical application of inhibitors of fibrinolysis. ( Verstraete, M, 1985) |
| "Eleven patients with advanced ovarian carcinoma who had large quantities of ascites during the course of previous chemotherapy were tested with intraperitoneal injections of tranexamic acid, followed by combination chemotherapy." | 3.67 | Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites. ( Kato, K; Kikuchi, Y; Kizawa, I; Matsuda, M; Oomori, K, 1986) |
| "The present study was designed to obtain an experimental tumor model as similar as possible to human ovarian cancer which often had a large amount of ascites and to assess the therapeutic value of tranexamic acid." | 3.67 | Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation. ( Kato, K; Kikuchi, Y; Kita, T; Kizawa, I; Miyauchi, M; Oomori, K; Sugita, M; Tenjin, Y, 1987) |
| "In the present phase II trial, 26 heavily pretreated patients with advanced recurrent ovarian carcinoma were treated with tranexamic acid, 4-6 g per os daily for at least 3 months." | 3.66 | Tranexamic acid for the treatment of advanced ovarian carcinoma. ( Johnsson, JE; Sigurdsson, K; Tropé, C, 1983) |
| "Ovarian cancer is the third most common gynaecological cancer worldwide, with an age-standardised incidence rate of 6." | 2.53 | Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer. ( Kietpeerakool, C; Laopaiboon, M; Lumbiganon, P; Supoken, A, 2016) |
| "Tranexamic acid was administered in 54 (60." | 1.48 | Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy. ( Bakkum-Gamez, JN; Borah, BJ; Cliby, WA; DeJong, SR; Dowdy, SC; Halverson, JW; Higgins, AA; Jankowski, CJ; Kor, DJ; Moriarty, JP; Otto, HA; Wallace, SK; Weaver, AL; Weinhold, MR, 2018) |
| "A patient with inoperable advanced ovarian cancer with metastases and ascites who had received several courses of radiotherapy and chemotherapy is presented." | 1.26 | Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid). ( Miyashita, T; Nakamura, A; Sashida, T; Soma, H; Yoshida, M, 1980) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (64.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 1 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Yang, X | 1 |
| Chai, M | 1 |
| Xia, L | 1 |
| He, Z | 1 |
| Wu, X | 1 |
| Zhang, J | 1 |
| Wallace, SK | 1 |
| Halverson, JW | 1 |
| Jankowski, CJ | 1 |
| DeJong, SR | 1 |
| Weaver, AL | 1 |
| Weinhold, MR | 1 |
| Borah, BJ | 1 |
| Moriarty, JP | 1 |
| Cliby, WA | 1 |
| Kor, DJ | 1 |
| Higgins, AA | 1 |
| Otto, HA | 1 |
| Dowdy, SC | 1 |
| Bakkum-Gamez, JN | 1 |
| Lemoine, A | 1 |
| Lambaudie, E | 1 |
| Bonnet, F | 1 |
| Leblanc, E | 1 |
| Alfonsi, P | 1 |
| Lundin, ES | 1 |
| Johansson, T | 1 |
| Zachrisson, H | 1 |
| Leandersson, U | 1 |
| Bäckman, F | 1 |
| Falknäs, L | 1 |
| Kjølhede, P | 1 |
| Kietpeerakool, C | 1 |
| Supoken, A | 1 |
| Laopaiboon, M | 1 |
| Lumbiganon, P | 1 |
| Sigurdsson, K | 1 |
| Johnsson, JE | 1 |
| Tropé, C | 2 |
| Astedt, B | 2 |
| Soma, H | 1 |
| Sashida, T | 1 |
| Yoshida, M | 1 |
| Miyashita, T | 1 |
| Nakamura, A | 1 |
| Glifberg, I | 1 |
| Mattsson, W | 1 |
| Rutqvist, LE | 1 |
| Bolund, C | 1 |
| Friberg, S | 1 |
| Einhorn, N | 1 |
| Wallgren, A | 1 |
| Verstraete, M | 1 |
| Kikuchi, Y | 3 |
| Kizawa, I | 3 |
| Oomori, K | 3 |
| Kuki, E | 1 |
| Kato, K | 3 |
| Matsuda, M | 1 |
| Miyauchi, M | 1 |
| Kita, T | 1 |
| Sugita, M | 1 |
| Tenjin, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| IV Tranexamic Acid Prior to Hysterectomy for Reduction of Intraoperative Blood Loss: A Randomized Placebo-Controlled Trial[NCT02911831] | Early Phase 1 | 71 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Efficacy and Safety of Tranexamic Acid in Cytoreductive Surgery for Ovarian Cancer[NCT04360629] | 151 participants (Actual) | Interventional | 2020-06-03 | Completed | |||
| Efficacy in Controlling Bleeding Post-coronary Bypass Surgery Using Combination of Local Application of Tranexamic Acid and Intravenous Tranexamic Compared to Intravenous Tranexamic Acid Alone. A Randomized Controlled Trial[NCT01600599] | 40 participants (Actual) | Interventional | 2011-01-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for tranexamic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
[Perioperative care of epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY under the aegis of CNGOF a
Topics: Analgesia, Patient-Controlled; Anemia; Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ova | 2019 |
Effectiveness of tranexamic acid in reducing blood loss during cytoreductive surgery for advanced ovarian cancer.
Topics: Adult; Antifibrinolytic Agents; Blood Loss, Surgical; Blood Transfusion; Cytoreduction Surgical Proc | 2016 |
Clinical application of inhibitors of fibrinolysis.
Topics: 4-Aminobenzoic Acid; Aminocaproic Acid; Angioedema; Antifibrinolytic Agents; Aprotinin; Blood Preser | 1985 |
2 trials available for tranexamic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Intraoperative use of tranexamic acid to reduce blood loss during cytoreductive surgery for advanced ovarian cancer: A randomized controlled clinical trial.
Topics: Antifibrinolytic Agents; Blood Loss, Surgical; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical | 2023 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
Single-dose tranexamic acid in advanced ovarian cancer surgery reduces blood loss and transfusions: double-blind placebo-controlled randomized multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Antifibrinolytic Agents; Blood Loss, Surgical; Double-Blind Method; | 2014 |
9 other studies available for tranexamic acid and Ovarian Neoplasms
| Article | Year |
|---|---|
Optimizing Blood Transfusion Practices Through Bundled Intervention Implementation in Patients With Gynecologic Cancer Undergoing Laparotomy.
Topics: Aged; Antifibrinolytic Agents; Blood Transfusion; Endometrial Neoplasms; Female; Humans; Laparotomy; | 2018 |
Tranexamic acid for the treatment of advanced ovarian carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Carcinoma; Cyclohexanecarboxylic Acids; Drug | 1983 |
Adjuvant treatment of ovarian carcinoma with tranexamic acid.
Topics: Adenocarcinoma; Cyclohexanecarboxylic Acids; Cystadenoma; Female; Humans; Ovarian Neoplasms; Plasmin | 1980 |
Treatment of advanced ovarian cancer with fibrinolytic inhibitor (tranexamic acid).
Topics: Cyclohexanecarboxylic Acids; Female; Fibrinolysis; Humans; Middle Aged; Ovarian Neoplasms; Tranexami | 1980 |
Arrest of growth of ovarian tumor by tranexamic acid.
Topics: Adenocarcinoma, Papillary; Cyclohexanecarboxylic Acids; Drug Therapy, Combination; Female; Heparin; | 1977 |
[Treatment of advanced cancer with Cyclocapron (tranexamic acid)].
Topics: Adenocarcinoma; Adult; Aged; Breast Neoplasms; Cyclohexanecarboxylic Acids; Female; Humans; Melanoma | 1977 |
The inhibitory effect of tranexamic acid on human ovarian carcinoma cell grown in vitro and in vivo.
Topics: Adenocarcinoma; Animals; Carcinoma, Squamous Cell; Cell Line; Colony-Forming Units Assay; Cyclohexan | 1986 |
Adjuvant effects of tranexamic acid to chemotherapy in ovarian cancer patients with large amount of ascites.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Ascitic Fluid; Carcinoma; Cyclohexanecarboxyl | 1986 |
Establishment of a human ovarian cancer cell line capable of forming ascites in nude mice and effects of tranexamic acid on cell proliferation and ascites formation.
Topics: Animals; Ascites; Cell Division; Cell Line; Cisplatin; Cyclohexanecarboxylic Acids; Drug Synergism; | 1987 |